Semustine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Semustine
Accession Number
DB13647
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Synonyms
Not Available
External IDs
ICIG 1110 / ICIG-1110
Categories
UNII
6YY7T1T567
CAS number
13909-09-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Semustine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Semustine.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Semustine.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Semustine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Semustine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Semustine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Semustine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Semustine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Semustine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Semustine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Semustine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Semustine.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Semustine.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Semustine.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Semustine.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Semustine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Semustine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Semustine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Semustine.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Semustine.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Semustine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Semustine
ATC Codes
L01AD03 — Semustine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentLeukaemia, Acute / Myelodysplastic Syndromes1
2RecruitingTreatmentMyelodysplastic Syndromes1
3CompletedTreatmentAstrocytomas / Glioblastomas1
3CompletedTreatmentColorectal Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:45 / Updated on July 02, 2018 19:54